sam1933       

Overview

Stocks

Stats

Community

Widget

Last Activity: Added CYTR to bullish list on 11/04/09  Current Stock List: Symbol SP Sentiment Rating Return Since CYTR +21.38% 11/04/09 STEM -6.03% 10/30/09 ENMD +76.00% 10/23/09 XYNH N/A n/a 10/22/09 TELK N/A -3.69% 10/21/09 NNVC n/a 10/21/09 FRE -6.45% 10/21/09 ACTC n/a 10/20/09 INIX N/A n/a 10/20/09 All-time Sectors of Interest ... View All > Opinion & Analysis keep your eyes on xynh.. NEWS EXPECTED ANYTIME!!!   about XYNH   11/19/09 <table width="100%"> <tbody> <tr> <td> Xynergy has developed a working prototype of a product that converts traditional g... Advanced Cell Technology Files IND With FDA For Fir..   about ACTC   11/19/09   Advanced Cell Technology, Inc. ( OTCBB:ACTC ) announced today that it filed an Investigational New Drug (IND) Application with the US Food and Drug Administration (FDA) to initiate a Phas... Coalition Against Loan Modification Fraud   about FRE   11/19/09 MCLEAN, Va., Nov 18, 2009 /PRNewswire-FirstCall via COMTEX/ -- The following statement was released today by Jeffery Markowitz, Vice President of Government and Industry Relations, Freddie Mac (NYSE: ... Freddie Mac Applauds Columbus, Ohio Coalition Again..   about FRE   11/19/09 "We look forward to working with the Treasury Department, the Federal Trade Commission, the U.S. Department of Housing and Urban Development, the Columbus Housing Partnership, NeighborWorks(R) Ame FORM 4   about TELK   11/19/09 <font> http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=690260... </font> <font> http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=690259... </font> <...

Discussions

CytRx to Initiate Phase 2 Clinical Trial with INNO-206 in... 11/19/09
CytRx to Initiate Phase 2 Clinical Trial with INNO-206 in Patients with Advanced Gastric Cancer CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company, today announced plans to initiate an open-label, multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a second-line treatment in patients with advanced gastric (stomach) cancer. CytRx President a...

Meeting with FDA 11/19/09
StemCells, Inc. Provides Update on NCL Program Meeting with FDA StemCells, Inc. (NASDAQ: STEM) today provided an update on the ongoing clinical development program of its proprietary HuCNS-SC® product candidate (purified human neural stem cells) for neuronal ceroid lipofuscinosis (NCL), often referred to as Batten disease. On November 6, 2009, representatives of StemCells, Inc...

(VNTA 11/15/09
Ventana Biotech has filed GB200910102 claiming chewing gum compositions comprising 2-hydroxyoleic acid and extracts of Hoodia gordonii with appetite suppressant activity. The application also names Anders Jenson as co-assignee. On July 28, 2009, the day before the UK Intellectual Property Office published this unusually informative title, the Swiss company issued a press release menti...

IMMEDIATE BUY:Ventana Biotech (VNTA) 11/15/09
Ventana Biotech (VNTA) is rocking the anti-obesity segment of the health care industry with news of a chewing gum that releases targeted hormonal triggers into the body with each chew. You feel full, even when you're not. Royalty cash flow from an anti-obesity drug is estimated at $1.5 to $1.7 billion a year. Holding the key to this billion-dollar medical breakthrough is a young, under-the-...

NanoViricides, Inc. to Present Anti-Influenza Drug Candid... 11/09/09
NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that the Company’s CEO, Eugene Seymour, MD, MPH, has been invited to participate in a panel discussion at the Influenza Congress USA 2009, in Washington DC on November 19th (www.terrapinn.com/usaflu). The discussion will center on the “Evolving Role of Anti-Virals” in influenza treatment. Dr. Seymour will review the Com...

CytRx Corporation's oncology pipeline 11/07/09
CytRx Corporation's oncology pipeline includes three clinical-stage drug candidates in various stages of development, including: Tamibarotene (formerly known as TM-411, TOS-80T, Am-80, and INNO-507) is an orally available, rationally designed, synthetic retinoid compound which was designed to potentially avoid toxic side effects by binding to its molecular target more selectively than a...

Re: Bullish on STEM ... 11/07/09
Significant recent events include: • In September 2009, StemCells announced the publication of preclinical data demonstrating the therapeutic potential of its HuCNS-SC ® product candidate (purified human neural stem cells) in neuronal ceroid lipofuscinosis (NCL), often referred to as Batten disease, a fatal neurodegenerative disorder in children. The Company’s neural stem cells, when tr...

Data for EntreMed's ENMD-2076 to Be Presented at the Upco... 11/04/09
Data from the ENMD-2076 Phase 1 Leukemia Trial to be Included ROCKVILLE, Md., Nov. 3 /PRNewswire-FirstCall/ -- EntreMed, Inc. (NASDAQ: ENMD) , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced presentations for its Aurora A/angiogenic kinase inhibitor, ENMD-2076, at the AACR-NCI-EORTC International Conference on Molecular Targets and ...

Re: CIT Group Files Bankruptcy, Seeks to Cut $10 Billion in Debt.. 11/04/09
Oops... my(browser's) mistake: CIT Group Inc. (NYSE: CIT) stated that it may be forced to file for bankruptcy and is currently considering an offer of financing from Citigroup Inc. (NYSE: C) and Barclays Capital. Bondholders are also seeking to provide about $2 billion in loans as a restructuring deadline approaches tomorrow. About $9.14 billion of CIT loans and bonds mature next year, includin...

potential new therapy for connatal Pelizaeus-Merzbacher D... 11/01/09
PMD Clinical Trial In the winter of 2009/10, UCSF Children's Hospital will begin a Phase I safety study sponsored by StemCells, Inc. for a potential new therapy for connatal Pelizaeus-Merzbacher Disease (PMD), which is a rare inherited condition involving the central nervous system. Children with PMD are unable to form myelin. As a result, children have impaired function in language developmen...




People Following sam1933 ...

Nobody is following sam1933.